Related Experiment Video
Updated: Jun 10, 2026
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Targeting the prostate-specific membrane antigen for prostate cancer therapy
Patrick Bühler1, Philipp Wolf, Ursula Elsässer-Beile
1Department of Urology, Experimental Urology, University of Freiburg, Breisacher Strasse 117, Freiburg, Germany.
Abstract:
Prostate cancer remains a leading cause of death for men in Western civilization. Despite the effectiveness of surgical prostatectomy, radiotherapy and hormonal therapy, a significant proportion of patients progress to advanced metastatic disease for which there are currently no curative treatment options. Therefore, new therapeutic approaches need to be considered. The prostate-specific membrane antigen is a cell-surface glycoprotein that is highly and specifically expressed on prostate epithelial cells and strongly upregulated in prostate cancer at all stages. These characteristics make it an attractive target for antibody-based imaging and therapies and the first anti-prostate-specific membrane antigen agents have already entered clinical trials. The proposed strategies include targeted toxins and radiotherapeutics as well as immunotherapeutic agents and vaccines.
Insights
New prostate cancer therapies targeting the prostate-specific membrane antigen (PSMA) show promise for advanced disease. Antibody-based treatments are being developed for improved imaging and therapeutic strategies.
Area of Science:
- Oncology
- Immunology
- Radiochemistry
Background:
- Prostate cancer is a significant cause of male mortality.
- Current treatments like surgery, radiotherapy, and hormonal therapy are insufficient for advanced metastatic disease.
- Novel therapeutic strategies are essential for patients with no curative options.
Purpose of the Study:
- To explore the potential of prostate-specific membrane antigen (PSMA) as a therapeutic target.
- To review emerging antibody-based imaging and therapeutic agents targeting PSMA.
- To discuss various treatment modalities including targeted toxins, radiotherapeutics, immunotherapy, and vaccines.
Main Methods:
- Review of current literature on prostate cancer treatments.
- Analysis of PSMA expression patterns in prostate cancer.
- Evaluation of preclinical and clinical data for PSMA-targeted agents.
Main Results:
- Prostate-specific membrane antigen (PSMA) is highly and specifically expressed on prostate cancer cells across all stages.
- PSMA's characteristics make it an ideal target for antibody-based therapies.
- Early clinical trials of anti-PSMA agents are underway.
Conclusions:
- Targeting PSMA offers a promising new avenue for treating advanced prostate cancer.
- Antibody-based strategies, including toxins, radiotherapeutics, and immunotherapies, are under investigation.
- Further development of PSMA-targeted agents could lead to improved outcomes for prostate cancer patients.
